U.S. dietary guidelines state that even low amounts of alcohol – less than a single drink a day – increase cancer risk.

Capivasertib is taken as a twice-daily pill, in combination with the hormone therapy fulvestrant. The drug works by blocking ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

A new research perspective was published in , Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of ...

Carnegie Mellon University’s Summer Undergraduate Research Fellowship (SURF) program provides funding for undergraduates to work full time on research projects during the summer. Many students ...

Canada Gairdner Awards recognize the world’s most accomplished researchers whose work is improving our understanding of human ...

The National Institute for Health and Care Excellence has now approved capivasertib for use on the NHS - we look at who could ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver ...

A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is a “landmark moment”.

Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients.

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.